|
||||||||
![]() |
||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
The vector sequence has been compiled using the information from sequence databases, published literature, and other sources, together with partial sequences obtained by Evrogen. This vector has not been completely sequenced. |
|||||||||||||||||||||||||||||||||||||||||||||||||
![]() Download
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
pmKate2-actinin is a mammalian expression vector encoding mKate2-actinin fusion protein (see reporter description). The vector can be used for fluorescent labeling of
![]() | N-terminal mKate2 fusion construct with human non-muscle |
mKate2 codon usage is optimized for high expression in mammalian cells (humanized) [Haas et al., 1996]. Human
pmKate2-actinin vector can be used as a source of mKate2-actinin hybrid sequence. The vector backbone contains unique restriction sites that permit its excision and further insertion into expression vector of choice.
Note: The plasmid DNA was isolated from dam+-methylated
The vector backbone contains immediate early promoter of cytomegalovirus (PCMV IE) for protein expression, SV40 origin for replication in mammalian cells expressing SV40 T-antigen, pUC origin of replication for propagation in
SV40 early promoter (PSV40) provides neomycin resistance gene (Neor) expression to select stably transfected eukaryotic cells using G418. Bacterial promoter (P) provides kanamycin resistance gene expression (Kanr) in
Expression in mammalian cells
pmKate2-actinin vector can be transfected into mammalian cells by any known transfection method. CMV promoter provides strong, constitutive expression of the mKate2-actinin fusion in eukaryotic cells. If required, stable transformants can be selected using G418 [Gorman, 1985].
Propagation in
Suitable host strains for propagation in
Location of features
PCMV IE: 1-589
Enhancer region: 59-465
TATA box: 554-560
Transcription start point: 583
actinin-mKate2 fusion: 637-4068
alpha-actinin: 637-3312
Start codon (ATG): 637-639
Last amino acid in alfa-Actinin: 3310-3312
mKate2: 3370-4068
Stop codon: 4066-4068
SV40 early mRNA polyadenylation signal
Polyadenylation signals: 4221-4226 & 4250-4255
mRNA 3' ends: 4259 & 4271
f1 single-strand DNA origin: 4318-4773
Bacterial promoter for expression of Kanr gene
-35 region: 4835-4840
-10 region: 4858-4863
Transcription start point: 4870
SV40 origin of replication: 5114-5249
SV40 early promoter
Enhancer (72-bp tandem repeats): 4947-5018 & 5019-5090
21-bp repeats: 5094-5114, 5115-5135 & 5137-5157
Early promoter element: 5170-5176
Major transcription start points: 5166, 5204, 5210 & 5215
Kanamycin/neomycin resistance gene
Neomycin phosphotransferase coding sequences:
Start codon (ATG): 5298-5300
Stop codon: 6090-6092
G->A mutation to remove Pst I site: 5480
C->A (Arg to Ser) mutation to remove BssH II site: 5826
Herpes simplex virus (HSV) thymidine kinase (TK) polyadenylation signal
Polyadenylation signals: 6328-6333 & 6341-6346
pUC plasmid replication origin: 6677-7320
Evrogen Fluorescent Protein Products (the Products) are intended for research use only. The Products are covered by Evrogen Patents and/or Patent applications pending. By use of these Products, you accept the terms and conditions of the applicable Limited Use Label License.
The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839, and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.
|
Copyright 2002-2011 Evrogen. All rights reserved. Evrogen JSC, 16/10 Miklukho-Maklaya str., Moscow, Russia, Tel +7(495)988-4084, Fax +7(495)988-4085, e-mail:evrogen@evrogen.com |